710547Proveca Paediatric Ibuprofen IV (Powder for Reconstitution)ClosedGRD Proof of ConceptInnovate UKWith today’s major research and development activities of pharmaceutical companies focused on meeting the needs of an increasingly aging population, children who represent the bulk of the dependent population worldwide still remain a widely neglected niche market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to receive age-appropriate drug information continues to have a major effect on all areas of paediatric pharmaceuticals. Proveca has been formed to develop and license essential medicines for children and make them available in appropriate formats, to satisfy unmet priority health care needs of the paediatric population (as defined on the EMA paediatric priority list). Proveca plans to develop an intravenous (IV) formulation of the off-patent drug ibuprofen (as a powder for reconstitution with water for injection), for the treatment of pain and fever in children. Acute pain is a significant problem and can occur following acute illness or disease processes, trauma or operative procedures. There are currently no licensed IV formulations of ibuprofen for the treatment of pain and fever in children in the EU. The introduction of this new product has the potential to improve the management of pain and fever in children by increasing choice and decreasing the use of opiate drugs, which are associated with unwanted side-effects. The funding will enable Proveca to develop a formulation suitable for clinical trial use and ready for scale up and manufacture. The new IV formulation, as a powder for reconstitution, will considerably reduce the risk of post-surgical complications, particularly related to opioid analgesics, decrease the cost of medical care and accelerate recovery and a return to normal activities of daily living.